196 related articles for article (PubMed ID: 35836470)
1. Epithelial to Mesenchymal Transition Relevant Subtypes with Distinct Prognosis and Responses to Chemo- or Immunotherapies in Osteosarcoma.
Zhou Y; Li G; Li H; Lai F; Duan P; Cheng M
J Immunol Res; 2022; 2022():1377565. PubMed ID: 35836470
[TBL] [Abstract][Full Text] [Related]
2. Identification of 9-Gene Epithelial-Mesenchymal Transition Related Signature of Osteosarcoma by Integrating Multi Cohorts.
Yiqi Z; Ziyun L; Qin F; Xingli W; Liyu Y
Technol Cancer Res Treat; 2020; 19():1533033820980769. PubMed ID: 33308057
[TBL] [Abstract][Full Text] [Related]
3. Integrating bulk and single-cell RNA sequencing data reveals epithelial-mesenchymal transition molecular subtype and signature to predict prognosis, immunotherapy efficacy, and drug candidates in low-grade gliomas.
Wang C; He Z
Front Pharmacol; 2023; 14():1276466. PubMed ID: 38053842
[No Abstract] [Full Text] [Related]
4. Characterizing the critical role of metabolism in osteosarcoma based on establishing novel molecular subtypes.
Zhang WB; Han FM; Liu LM; Jin HB; Yuan XY; Shang HS
Eur Rev Med Pharmacol Sci; 2022 Apr; 26(8):2926-2943. PubMed ID: 35503637
[TBL] [Abstract][Full Text] [Related]
5. Identification of an EMT-related gene-based prognostic signature in osteosarcoma.
Gong H; Tao Y; Xiao S; Li X; Fang K; Wen J; Zeng M; Liu Y; Chen Y
Cancer Med; 2023 Jun; 12(11):12912-12928. PubMed ID: 37102261
[TBL] [Abstract][Full Text] [Related]
6. Machine learning survival prediction using tumor lipid metabolism genes for osteosarcoma.
Li S; Zheng Z; Wang B
Sci Rep; 2024 Jun; 14(1):12934. PubMed ID: 38839983
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of apoptosis-related signature and molecular subtype to improve prognosis prediction in osteosarcoma patients.
Hong J; Li Q; Wang X; Li J; Ding W; Hu H; He L
J Clin Lab Anal; 2022 Jul; 36(7):e24501. PubMed ID: 35576501
[TBL] [Abstract][Full Text] [Related]
8. Construction of a 5-gene prognostic signature based on oxidative stress related genes for predicting prognosis in osteosarcoma.
Hong X; Fu R
PLoS One; 2023; 18(12):e0295364. PubMed ID: 38039294
[TBL] [Abstract][Full Text] [Related]
9. EMT transcription factors: implication in osteosarcoma.
Yang G; Yuan J; Li K
Med Oncol; 2013 Dec; 30(4):697. PubMed ID: 23975634
[TBL] [Abstract][Full Text] [Related]
10. Gene Expression Classifier Reveals Prognostic Osteosarcoma Microenvironment Molecular Subtypes.
Song YJ; Xu Y; Deng C; Zhu X; Fu J; Chen H; Lu J; Xu H; Song G; Tang Q; Wang J
Front Immunol; 2021; 12():623762. PubMed ID: 33959121
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of a robust epithelial-mesenchymal transition (EMT)-related prognostic signature for hepatocellular carcinoma.
Chen S; Zhao E
Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101587. PubMed ID: 33662631
[TBL] [Abstract][Full Text] [Related]
12. Anoikis patterns exhibit distinct prognostic and immune landscapes in Osteosarcoma.
Zhang Z; Zhu Z; Fu J; Liu X; Mi Z; Tao H; Fan H
Int Immunopharmacol; 2023 Feb; 115():109684. PubMed ID: 36630752
[TBL] [Abstract][Full Text] [Related]
13. Establishing a Prognostic Signature Based on Epithelial-Mesenchymal Transition-Related Genes for Endometrial Cancer Patients.
Liu J; Cui G; Shen S; Gao F; Zhu H; Xu Y
Front Immunol; 2021; 12():805883. PubMed ID: 35095892
[TBL] [Abstract][Full Text] [Related]
14. Necrotizing apoptosis-related genes prognosis and treatment effect analysis of osteosarcoma in children.
Chen Y; Wu L; Li Y; Zheng J; Zhong S; Gu S; Chen J
J Gene Med; 2024 Jan; 26(1):e3646. PubMed ID: 38100138
[TBL] [Abstract][Full Text] [Related]
15. A novel molecular signature for predicting prognosis and immunotherapy response in osteosarcoma based on tumor-infiltrating cell marker genes.
Tang H; Liu S; Luo X; Sun Y; Li X; Luo K; Liao S; Li F; Liang J; Zhan X; Wei Q; Liu Y; He M
Front Immunol; 2023; 14():1150588. PubMed ID: 37090691
[TBL] [Abstract][Full Text] [Related]
16. A CIC-related-epigenetic factors-based model associated with prediction, the tumor microenvironment and drug sensitivity in osteosarcoma.
Yu B; Geng C; Wu Z; Zhang Z; Zhang A; Yang Z; Huang J; Xiong Y; Yang H; Chen Z
Sci Rep; 2024 Jan; 14(1):1308. PubMed ID: 38225273
[TBL] [Abstract][Full Text] [Related]
17. An EMT-based risk score thoroughly predicts the clinical prognosis, tumor immune microenvironment and molecular subtypes of bladder cancer.
Xiao Z; Cai Z; Deng D; Tong S; Zu X
Front Immunol; 2022; 13():1000321. PubMed ID: 36211349
[TBL] [Abstract][Full Text] [Related]
18. Construction of an ER stress-related prognostic signature for predicting prognosis and screening the effective anti-tumor drug in osteosarcoma.
Chen W; Liao Y; Sun P; Tu J; Zou Y; Fang J; Chen Z; Li H; Chen J; Peng Y; Wen L; Xie X
J Transl Med; 2024 Jan; 22(1):66. PubMed ID: 38229155
[TBL] [Abstract][Full Text] [Related]
19. Molecular subtypes of osteosarcoma classified by cancer stem cell related genes define immunological cell infiltration and patient survival.
Guo L; Yan T; Guo W; Niu J; Wang W; Ren T; Huang Y; Xu J; Wang B
Front Immunol; 2022; 13():986785. PubMed ID: 36059448
[TBL] [Abstract][Full Text] [Related]
20. Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma cancer.
Liu R; Hu Y; Liu T; Wang Y
BMC Cancer; 2021 Dec; 21(1):1345. PubMed ID: 34922489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
